QUARTERLY STATEMENT

1st quarter 2021



Optimistic about the full year following a good first quarter—Forecast specified in more detail

- Higher demand worldwide and improved prices increased sales
- Adjusted EBITDA grew by 15 percent to €588 million
- All chemicals divisions reported higher earnings
- Adjusted net income improved by 32 percent to €239 million
- High free cash flow of €312 million
- Outlook for 2021 specified in more detail: adjusted EBITDA now expected to be between €2.1 billion and €2.3 billion

Key figures for the Evonik Group

	1st qu	1st quarter	
in € million	2020	2021	
Sales	3,243	3,358	
Adjusted EBITDA ^a	513	588	
Adjusted EBITDA margin in %	15.8	17.5	
Adjusted EBIT ^b	273	336	
Income before financial result and income taxes, continuing operations (EBIT)	247	308	
Net income	130	186	
Adjusted net income	181	239	
Earnings per share in €	0.28	0.40	
Adjusted earnings per share in €	0.39	0.51	
Cash flow from operating activities	297	494	
Cash outflows for investments in intangible assets, property, plant and equipment ^c	-184	-182	
Free cash flow ^d	113	312	
Net financial debt as of March 31	-2,778	-2,704	
No. of employees (continuing operations) as of March 31	32,770	32,745	

^a Earnings before financial result, taxes, depreciation, and amortization, after adjustments, continuing operations.

^b Earnings before financial result and taxes, after adjustments, continuing operations.

^c Investments in intangible assets, property, plant and equipment, continuing operations.


^d Cash flow from operating activities, continued operations, less cash outflows for investments in intangible assets, property, plant and equipment.

Due to rounding, some figures in this report may not add up exactly to the totals stated.


CONTENTS

Business conditions and performance	2
Business performance	2
Performance of the divisions	5
Financial condition	12
Expected development	13
Income statement	15
Balance sheet	16
Cash flow statement	17
Segment report	18
Appendix	20
Financial calendar	21
Credits	21

Sales by division—1st quarter



Sales by region^a—1st quarter



Business conditions and performance

1. Business performance


Major events

The **coronavirus** pandemic is continuing to affect people's lives and economic activity around the world in 2021. Evonik took the necessary precautions to protect its employees at an early stage in order to prevent the virus from spreading within the company while continuing to operate as best possible. We are continuing to analyze the present situation on a daily basis so that we can take timely action.

Our business performance in the first quarter of 2021 was only marginally impacted by the coronavirus pandemic. Our supply chains have remained intact, and we have sufficient liquidity, as well as firmly committed credit facilities that have not yet been utilized.

Business performance in Q1 2021

Our business developed well in the first quarter of 2021. We registered high demand worldwide and were able to increase volume sales considerably. Sales and adjusted EBITDA improved year-on-year. The chemicals divisions all reported higher earnings.




Sales by quarter

The Evonik Group's **sales** increased by 4 percent to €3,358 million. Organic sales growth was 8 percent, driven by higher volumes and improved selling prices. By contrast, exchange rates had a negative effect.

Year-on-year change in sales

in %	1st quarter 2021
Volumes	5
Prices	3
Organic sales growth	8
Exchange rates	-4
Change in the scope of consolidation/other effects	-
Total	4

Adjusted EBITDA by quarter



Adjusted EBITDA rose 15 percent to €588 million, mainly due to higher volumes and the improvement in selling prices. The adjusted EBITDA margin increased from 15.8 percent in the prior-year period to 17.5 percent.

Statement of income

	1st quarter		
in € million	2020	2021	Change in %
Sales	3,243	3,358	4
Adjusted EBITDA	513	588	15
Adjusted depreciation, amortization, and impairment losses	-240	-252	
Adjusted EBIT	273	336	23
Adjustments	-26	-28	
thereof restructuring	-1	-3	
thereof impairment losses/reversals of impairment losses		-	
thereof acquisition/divestment of shareholdings	-22	-4	
thereof other	-3	-21	
Income before financial result and income taxes, continuing operations (EBIT)	247	308	25
Financial result	-50	-21	
Income before income taxes, continuing operations	197	287	46
Income taxes	-57	-88	
Income after taxes, continuing operations	140	199	42
Income after taxes, discontinued operations	-6	-7	
Income after taxes	134	192	43
thereof attributable to non-controlling interests	4	6	
Net income	130	186	43
Earnings per share in €	0.28	0.40	

Expenses in connection with the end of a legal dispute, which are recognized in the line item "Other", are the biggest single item in the **adjustments** of -€28 million. In the prior-year period, the adjustments mainly comprised expenses in connection with the acquisition of PeroxyChem. The **financial result** improved to -€21 million as interest expense was lower. **Income before income taxes, continuing operations,** rose by 46 percent to €287 million. The income tax rate on the continuing operations was 31 percent, and the adjusted income tax rate was 30 percent. Income after taxes, discontinued operations, contained post-divestment expenses from divestments in previous periods. **Net income** was 43 percent higher at €186 million.

Adjusted net income improved by 32 percent to €239 million. Adjusted earnings per share increased from €0.39 to €0.51.

5

Reconciliation to adjusted net income

	1st quarter		
in € million	2020	2021	Change in %
Adjusted EBITDA	513	588	15
Adjusted depreciation, amortization, and impairment losses	-240	-252	
Adjusted EBIT	273	336	23
Adjusted financial result	-51	-21	
Amortization and impairment losses on intangible assets	33	36	
Adjusted income before income taxes ^a	255	351	38
Adjusted income taxes	-70	-106	
Adjusted income after taxes ^a	185	245	32
thereof adjusted income attributable to non-controlling interests	4	6	
Adjusted net income ^a	181	239	32
Adjusted earnings per share in €	0.39	0.51	

EVONIK

^a Continuing operations.

2. Performance of the divisions

Specialty Additives

Key figures

		1st quarter		
in € million	2020	2021	Change in %	
External sales	852	907	6	
Adjusted EBITDA	239	273	14	
Adjusted EBITDA margin in %	28.1	30.1	_	
Adjusted EBIT	196	230	17	
Capital expenditures ^a	13	12	-8	
No. of employees as of March 31	3,631	3,678	1	


Prior-year figures restated.

^a Capital expenditures for intangible assets, property, plant and equipment.


The Specialty Additives division reported a 6 percent rise in sales to \in 907 million in the **first quarter of 2021**. This was driven by considerably higher volumes, while prices were stable. The increase was reduced by currency effects.

There was a significant upturn in demand for additives for the coatings industry in all regions, resulting in perceptible sales growth. Since demand for consumer durables continued to rise, we also registered a rise in sales of our additives for polyurethane foams, for example, for mattresses and refrigerators. Demand for products for renewable energies was good, especially in Asia, and demand for products for the construction industry remained robust.

Sales Specialty Additives



Adjusted EBITDA rose by 14 percent to €273 million, mainly because volumes were higher. The adjusted EBITDA margin improved from 28.1 percent to an excellent level of 30.1 percent.



Adjusted EBITDA Specialty Additives

2021 2020

Prior-year figures restated.

7

Nutrition & Care

Key figures


		1st quarter	
in € million	2020	2021	Change in %
External sales	748	780	4
Adjusted EBITDA	118	143	21
Adjusted EBITDA margin in %	15.8	18.3	_
Adjusted EBIT	54	78	44
Capital expenditures ^a	18	22	22
No. of employees as of March 31	5,280	5,281	_

Prior-year figures restated.

^a Capital expenditures for intangible assets, property, plant and equipment.

In the Nutrition & Care division, sales were 4 percent higher at \in 780 million in the **first quarter of 2021.** This was driven by an improvement in selling prices, along with a slight increase in volumes. However, the increase was held back by currency effects.

Essential amino acids posted stable sales. While demand remained good and selling prices increased, exchange rates had a negative effect. There was good demand for health and care products, resulting in higher sales in the health & care business. Active ingredients, especially for cosmetics applications, continued their positive development. Pharmaceutical applications had a slightly weaker start to the year for project-related reasons, but this is expected to be more than offset in subsequent quarters.




Sales Nutrition & Care

Prior-year figures restated.

Adjusted EBITDA advanced 21 percent to €143 million thanks to higher selling prices and active cost management. The adjusted EBITDA margin improved significantly from 15.8 percent in the prior-year period to 18.3 percent.

Adjusted EBITDA Nutrition & Care



Prior-year figures restated.

Smart Materials

Key figures

		1st quarter		
in € million	2020	2021	Change in %	
External sales	858	909	6	
Adjusted EBITDA	166	173	4	
Adjusted EBITDA margin in %	19.3	19.0	-	
Adjusted EBIT	108	108	-	
Capital expenditures ^a	83	59	-29	
No. of employees as of March 31	7,615	7,783	2	

Prior-year figures restated.


^a Capital expenditures for intangible assets, property, plant and equipment.

In the Smart Materials division, sales rose 6 percent to €909 million in the **first quarter of 2021.** This was driven by higher volumes and the initial consolidation of PeroxyChem (from February 2020) and Porocel (from November 2020). The improvement was held back by slightly lower selling prices and negative currency effects.


Looking at inorganic products, our business with silicas for tires benefited from a global economic upturn. Demand for products for the hygiene and care sectors and environmental applications remained robust. Our catalysts business benefited from the initial consolidation of the Porocel business, which was acquired in November 2020. Overall, inorganic products generated higher sales than in the prior-year period. In the polymers business, high-performance polymers registered good demand from the automotive industry. Our polyamide 12 powder for 3D printing also posted higher sales.

9

Sales Smart Materials



Adjusted EBITDA increased by 4 percent to €173 million, driven mainly by volumes. The adjusted EBITDA margin was 19.0 percent, which was around the prior-period level.



Adjusted EBITDA Smart Materials

Prior-year figures restated.

Performance Materials

Key figures


		1st quarter		
in € million	2020	2021	Change in %	
External sales	584	580	-1	
Adjusted EBITDA	18	42	133	
Adjusted EBITDA margin in %	3.1	7.2	-	
Adjusted EBIT	-12	10	-	
Capital expenditures ^a	10	8	-20	
No. of employees as of March 31	1,815	1,810	-	

Prior-year figures restated.

^a Capital expenditures for intangible assets, property, plant and equipment.

Sales fell 1 percent to €580 million in the Performance Materials division in the **first quarter of 2021**. Higher prices and negative currency effects almost canceled each other out.

Sales of C_4 products increased as demand picked up and selling prices rose. The development of the superabsorbents' business was held back by lower production as a result of storms.




Sales Performance Materials

Prior-year figures restated.

Adjusted EBITDA increased from €18 million to €42 million, mainly due to better product margins. The adjusted EBITDA margin increased from 3.1 percent in the prior-year period to 7.2 percent.

Adjusted EBITDA Performance Materials



Prior-year figures restated.

Technology & Infrastructure

Key figures

		1st quarter		
in € million	2020	2021	Change in %	
External sales	184	169	-8	
Adjusted EBITDA	34	29	-15	
Adjusted EBITDA margin in %	18.5	17.2	-	
Adjusted EBIT	8	2	-75	
Capital expenditures ^a	20	18	-10	
No. of employees as of March 31	8,681	8,510	-2	

Prior-year figures restated.

° Capital expenditures for intangible assets, property, plant and equipment.

Sales in the Technology & Infrastructure division declined by 8 percent to ≤ 169 million in the first quarter of 2021, principally due to weaker demand for services by external customers at our sites. Adjusted EBITDA declined by 15 percent to ≤ 29 million, mainly as a consequence of higher energy supply costs.

12 QUARTERLY STATEMENT Q1 2021

Financial condition

The cash flow from operating activities increased by ≤ 197 million to ≤ 494 million, principally because of the improved operating performance and lower tax payments. While cash outflows for investments in intangible assets, property, plant and equipment were basically unchanged, the **free cash flow** increased by ≤ 199 million to ≤ 312 million.

Cash flow statement (excerpt)

	1st quart	1st quarter	
in€million	2020	2021	
Cash flow from operating activities	297	494	
Cash outflows for investments in intangible assets, property, plant and equipment	-184	-182	
Free cash flow	113	312	
Cash flow from other investing activities	-100	129	
Cash flow from financing activities	-169	-73	
Change in cash and cash equivalents	-156	368	

The cash inflow of ≤ 129 million from other investing activities mainly resulted from the sale of current securities. The cash outflow for financing activities of ≤ 73 million mainly related to the repayment of financial debt.

Net financial debt was €2,704 million, a decrease of €182 million compared with December 31, 2020. This was mainly attributable to the high free cash flow.

Net financial debt

in€million	Dec. 31, 2020	Mar. 31, 2021
Non-current financial liabilities ^a	-3,564	-3,588
Current financial liabilities ^a	-368	-326
Financial debt	-3,932	-3,914
Cash and cash equivalents	563	936
Current securities	466	254
Other financial investments	17	20
Financial assets	1,046	1,210
Net financial debt	-2,886	-2,704

^a Excluding derivatives and excluding the refund liability for rebate and bonus agreements.

On April 20, 2021, Moody's altered Evonik's rating from Baa1 with a negative outlook to Baa2 with a stable outlook. Standard & Poor's rating is still BBB+ with a stable outlook. Both are still solid investment grade ratings.

In the first quarter of 2021, additions to property, plant and equipment and intangible assets (capital expenditures) totaled \in 130 million, which was below the prior-year figure of \in 198 million. In principle, there is a slight timing difference in cash outflows for property, plant and equipment. The biggest individual project is the construction of a production complex for the specialty polymer polyamide 12, which started in 2019. This facility is scheduled to come on stream in 2021.

Expected development

Progress with vaccinations to protect against coronavirus and expectations that the pandemic will subside should result in a clear global economic recovery in 2021. However, the **global economic situation** is still dominated by considerable uncertainty: while the accommodating monetary and fiscal policies around the world will likely be continued and should support the economic recovery, there are various risk factors such as the conflict between China and the USA as well as ongoing geopolitical tension and inflation risks. We have increased our forecast for economic growth in 2021 from 4.4 percent to 5.0 percent, mainly due to the expansionary monetary and fiscal policies in the USA.

Our forecast is based on the following assumptions:

- Economic development: 5.0 percent (previously: 4.4 percent)
- Euro/US dollar exchange rate: US\$1.20
- Internal raw material index: higher than in the prior year

Sales and earnings

Evonik still anticipates that **sales** will be between \in 12.0 billion and \in 14.0 billion in 2021 (2020: \in 12.2 billion). The growth divisions will benefit further from the resilience and quality they demonstrated in the coronavirus crisis and continue their long-term growth trend. In light of the positive start to the year overall, a strong first quarter, and the positive outlook for the second quarter, we are giving more detailed guidance for **adjusted EBITDA**. We now expect adjusted EBITDA to be between \in 2.1 billion and \in 2.3 billion, compared with our previous guidance of between \in 2.0 billion and \in 2.3 billion (2020: \in 1,906 million).

We expect the development of the chemical divisions to be as follows:

Despite the challenging conditions, in 2020, the Specialty Additives division was able to maintain its business performance at the pre-crisis level. This year, the division will once again benefit from its attractive business model, with high demand for customized, mission-critical solutions for customers. We therefore expect that this division's earnings will be slightly above the prior-year level (2020: €857 million).

For the Nutrition & Care division, we assume that the structural growth trend in our resilient end-markets will continue. We expect business in the consumer goods, nutrition, and healthcare areas to develop positively without cyclical exposure. Overall, we anticipate that this division's earnings will be well above the prior-year level ($2020: \in 560$ million).

In the Smart Materials division, we anticipate an unchanged, positive development in hygiene, personal care, and environmental applications. Moreover, this division should benefit from the ongoing recovery in the automotive and coatings end-markets. The PeroxyChem and Porocel acquisitions will also have a positive effect on sales and earnings. Overall, we expect earnings to be significantly higher year-on-year (2020: €529 million).

The Performance Materials division should report higher volumes than in the previous year and a significant improvement in margins. Overall, we assume that earnings in this division will be substantially above the low prior-year level (2020: €88 million).

The expected increase in raw material prices could have a slightly negative impact on the growth divisions; however, it should have positive effects for Performance Materials. Therefore, it should be balanced out overall across our portfolio.

The return on capital employed (ROCE) is expected to increase slightly year-on-year in 2021 (2020: 6.1 percent).

EVONIK

Financing and investments

We expect **cash outflows for investments in intangible assets, property, plant and equipment** to be around €900 million (2020: €956 million).

For the free cash flow, we expect the **cash conversion rate**¹ to reach the previous year's very good level of approximately 40 percent (2020: 41 percent; free cash flow: €780 million). This will be driven by the following positive factors: our high investment discipline, focused management of net working capital, and bonus and tax payments at an unchanged low level.

Forecast for 2021

Forecast performance indicators	2020	Forecast for 2021°	Revised forecast for 2021
	2020		
		Between €12.0 billion	Between €12.0 billion
Group sales	€12.2 billion	and €14.0 billion	and €14.0 billion
		Between €2.0 billion	Between €2.1 billion
Adjusted EBITDA	€1.9 billion	and €2.3 billion	and €2.3 billion
		Slightly above the	Slightly above the
ROCE	6.1%	prior-year level	prior-year level
Cash outflows for investments in intangible assets, property, plant and			
equipment	€956 million	Around €900 million	Around €900 million
Free cash flow: cash conversion rate ^b	41%	Around 40%	Around 40%

• As in the financial report 2020.

^b Ratio of free cash flow to adjusted EBITDA.

¹ Ratio of free cash flow to adjusted EBITDA.

Income statement

	1st qu	arter
in€million	2020	2021
Sales	3,243	3,358
Cost of sales	-2,324	-2,368
Gross profit on sales	919	990
Selling expenses	-394	-390
Research and development expenses	-109	-104
General administrative expenses	-125	-132
Other operating income	45	47
Other operating expense	-94	-105
Result from investments recognized at equity	5	2
Income before financial result and income taxes, continuing operations	247	308
Interest income	7	7
Interest expense	-47	-29
Other financial income/expense	-10	1
Financial result	-50	-21
Income before income taxes, continuing operations	197	287
Income taxes	-57	-88
Income after taxes, continuing operations	140	199
Income after taxes, discontinued operations	-6	-7
Income after taxes	134	192
thereof attributable to non-controlling interests	4	6
thereof attributable to shareholders of Evonik Industries AG (net income)	130	186
	0.28	0.40
thereof attributable to continuing operations	0.29	0.41
thereof attributable to discontinued operations	-0.01	-0.01

Balance sheet

in € million	Dec. 31, 2020	Mar. 31, 2021
Intangible assets	5,877	5,990
Property, plant and equipment	6,588	6,630
Right-of-use assets	668	661
Investments recognized at equity	75	81
Other financial assets	607	566
Deferred taxes	2,004	1,793
Other income tax assets	13	14
Other assets	102	102
Non-current assets	15,934	15,837
Inventories	1,806	1,996
Trade accounts receivable	1,455	1,721
Other financial assets	697	435
Other income tax assets	211	198
Other assets	231	304
Cash and cash equivalents	563	936
Current assets	4,963	5,590
Total assets	20,897	21,427
Issued capital	466	466
Capital reserve	1,167	1,171
Retained earnings including distributable profit	6,876	7,604
Treasury shares		-15
Other equity components	-497	-311
Equity attributable to shareholders of Evonik Industries AG	8,012	8,915
Equity attributable to non-controlling interests	87	84
Equity	8,099	8,999
Provisions for pensions and other post-employment benefits	4,618	3,879
Other provisions	715	641
Other financial liabilities	3,564	3,592
Deferred taxes	586	580
Other income tax liabilities	275	253
Other payables	114	117
Non-current liabilities	9,872	9,062
Other provisions	744	815
Trade accounts payable	1,273	1,470
Other financial liabilities	434	411
Other income tax liabilities	136	209
Other payables	339	461
Current liabilities	2,926	3,366
Total equity and liabilities	20,897	21,427

Cash flow statement

	1st qu	arter
in € million	2020	2021
Income before financial result and income taxes, continuing operations	247	308
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	240	251
Result from investments recognized at equity	-5	-2
Gains/losses on the disposal of non-current assets	15	-1
Change in inventories	-90	-158
Change in trade accounts receivable	-94	-229
Change in trade accounts payable	-18	210
Change in provisions for pensions and other post-employment benefits	18	25
Change in other provisions	23	47
Change in miscellaneous assets/liabilities	54	67
Cash inflows from dividends	13	11
Cash inflows/outflows for other income taxes	-106	-35
Cash flow from operating activities	297	494
Cash outflows for investments in intangible assets, property, plant and equipment	-184	-182
Cash outflows to obtain control of businesses ^a	-289	-2
Cash outflows relating to the loss of control over businesses		-78
Cash outflows for investments in other shareholdings	-9	-4
Cash inflows from divestments of intangible assets, property, plant and equipment	6	7
Cash inflows/outflows from divestment of other shareholdings	40	-
Cash inflows/outflows relating to securities, deposits, and loans	146	204
Cash inflows from interest	6	2
Cash flow from investing activities	-284	-53
Cash inflows/outflows relating to capital contributions	3	-
Cash outflows for dividends to non-controlling interests	-6	-6
Cash outflows for the purchase of treasury shares	-15	-15
Cash inflows from the addition of financial liabilities	228	81
Cash outflows for repayment of financial liabilities ^a	-356	-129
Cash inflows/outflows in connection with financial transactions	-8	12
Cash outflows for interest	-15	-16
Cash flow from financing activities	-169	-73
Change in cash and cash equivalents	-156	368
Cash and cash equivalents as of January 1	1,165	563
Change in cash and cash equivalents	-156	368
Changes in exchange rates and other changes in cash and cash equivalents	-10	5
Cash and cash equivalents as on the balance sheet as of March 31	999	936

^aPrior-year figures restated.

Segment report

Segment report by operating segments—1st quarter

	Specialty Additives		Nutrition & Care		Smart Materials	
in \in million	2020	2021	2020	2021	2020	2021
External sales	852	907	748	780	858	909
Internal sales	3	3	4	2	17	9
Total sales	855	910	752	782	875	918
Adjusted EBITDA	239	273	118	143	166	173
Adjusted EBITDA margin in %	28.1	30.1	15.8	18.3	19.3	19.0
Adjusted EBIT	196	230	54	78	108	108
Capital expenditures ^a	13	12	18	22	83	59
Financial investments		-	20	-	291	5
No. of employees as of March 31	3,631	3,678	5,280	5,281	7,615	7,783

Prior-year figures restated.

 $^{\rm o}$ For intangible assets, property, plant and equipment.

Segment report by regions—1st quarter

	Europe, Middle	e East & Africa	North America	
in € million	2020	2021	2020	2021
External sales ^a	1,650	1,642	775	773
Goodwill as of March 31 ^b	2,359	2,362	2,319	2,019
Other intangible assets, property, plant and equipment, and right-of-use assets as of March 31 ^b	4,507	4,726	2,201	2,172
Capital expenditures	127	109	61	16
No. of employees as of March 31	22,463	22,215	4,658	4,849

Prior-year figures restated.

^a External sales Europe, Middle East & Africa: thereof Germany €557 million (Q1 2020: €592 million).

^b Non-current assets according to IFRS 8.33 b.

Performance	Performance Materials Technology & Infrastructure		Infrastructure	Enabling functions, other activities, consolidation		Total Group (continuing operations)	
2020	2021	2020	2021	2020	2021	2020	2021
584	580	184	169	17	13	3,243	3,358
24	26	341	345	-389	-385		-
608	606	525	514	-372	-372	3,243	3,358
18	42	34	29	-62	-72	513	588
3.1	7.2	18.5	17.2	-	-	15.8	17.5
-12	10	8	2	-81	-92	273	336
10	8	20	18	54	11	198	130
_	-		-	2	1	313	6
1,815	1,810	8,681	8,510	5,748	5,683	32,770	32,745

•	Total C (continuing (Central & South America Asia-Pacific					
2021	2020	2021	2020	2021	2020		
3,358	3,243	794	679	149	139		
4,658	4,966	247	255	30	33		
8,623	8,554	1,634	1,730	91	116		
130	198	3	9	2	1		
32,745	32,770	5,001	4,997	680	652		

Appendix

Restatement of prior-year figures

Restatement in the segment report

Effective July 1, 2020, the executive board of Evonik Industries AG introduced a new **corporate structure**. The new chemicals divisions—Specialty Additives, Nutrition & Care, Smart Materials, and Performance Materials—are more balanced in terms of size and profitability. Moreover, clearer alignment to the technology platforms allows more selective management. As part of this, employees from the research and development units in the chemicals divisions were transferred to the support functions, which were reported in the Services segment until December 31, 2020. At the same time, the administrative functions were optimized.

The Western Europe, Eastern Europe, and Middle East & Africa **regions** were combined on July 1, 2020, so they can operate as one region in the future and respond to the upcoming challenges.

The **goodwill and identified hidden reserves** relating to former acquisitions of shares in Evonik Operations GmbH (Evonik Operations), which were previously reported in "Corporate, consolidation" in the segment report, have been allocated among the segments on a pro rata basis since December 31, 2020.

Effective January 1, 2021, the executive board of Evonik Industries AG further optimized the **functions** that support the executive board and the operating divisions. The executive board now decides on the allocation of resources and evaluates earnings power at the level of the Technology & Infrastructure division, which was previously part of the Services segment and is therefore now a reporting segment. This division provides technology and infrastructure services for the chemical industry and drives forward production-related innovation and digitalization. At the same time, the support functions formerly bundled in the Services segment have been combined with the former corporate functions to form enabling functions with global responsibility for supporting the executive board and the operating divisions.

The prior-year figures have been restated.

21

Financial calendar

Financial calendar 2021/22

Event	Date
Annual shareholders' meeting 2021	June 2, 2021
Interim report Q2 2021	August 5, 2021
Interim report Q3 2021	November 4, 2021
Report on Q4 2021 and FY 2021	March 3, 2022

EVONIK

Credits

Published by

Evonik Industries AG Rellinghauser Strasse 1–11 45128 Essen, Germany www.evonik.com

Contact

Communications Phone +49 201 177-3315 presse@evonik.com

Investor Relations Phone +49 201 177-3146 investor-relations@evonik.com

